Replies to post #53522 on Grapefruit USA Inc (GPFT)

[supercleetus]

pennies make all kinds of claims which is why you invest in them prudently, if at all. most who play this game shouldn't.

and company mismanagement is the penny stock investor's shield against everything...except much of the time the investor doesn't hold him/herself to the same level of accountability when investing in duds.

anyway, without a doubt this company was mismanaged right into bankruptcy and how that happened is ugly. (incidentally, the press release today was pretty forthcoming about that issue, which is refreshing.)

but it is interesting that with new management, they came out of bk although still with weak financing, defended one major case up through the SC, completed one major portion of 510k prep work (which I verified), started recruiting an advisory board, and so on.

giving them the benefit of the doubt for just a moment, if the transform rate is as claimed then it would be reasonable to look for a JV or maybe real (as opposed to fly by night) VC funding. we don't know whether that is happening or not. we do know that there has been a lot of debt restructuring during and after a bankruptcy. that may or may not seal the deal against more typical methods of funding.

re computational limits, that may be an issue but given the amount of literature out there, clearly that hasn't been enough to deter a lot of research in this field. nor have these limits prevented targeted applications from being developed and marketed. this is not new technology at its core. there are dental and veterinary applications out there now. but so far, with the semi-exception of the o-arm, no one has really chased a large bore device at least in the public eye.

there may be a second issue here which is that there hasn't been a good framework to evaluate these systems from either technical or regulatory perspectives. the fda piece i referred to previously from a couple of years ago basically states that.

that said, it also looks like that is changing, again from the FDA piece and from current literature. which, again assuming this company is on the up-and-up, is a good thing in case they re-submit.
so we're left with, "it can't be done" vs "it can't be evaluated" vs "it probably can be done but this isn't the company to do it" vs "they are headed in the right direction". investors have to decide that on their own.